Providing physicians, hospitals, and healthcare providers an end-to-end solution for patient centric care from rapid diagnosis through delivery of personalized therapies, streamlining care processes, minimizing expenses, and delivering transparency for payers.

Providing physicians, hospitals, and healthcare providers an end-to-end solution for patient centric care from rapid diagnosis through delivery of personalized therapies, streamlining care processes, minimizing expenses, and delivering transparency for payers.

Providing physicians, hospitals, and healthcare providers an end-to-end solution for patient centric care from rapid diagnosis through delivery of personalized therapies, streamlining care processes, minimizing expenses, and delivering transparency for payers.

NuGenerex

Immuno Oncology

IMMUNO-ONCOLOGY

AE37 immunotherapeutic vaccine for Breast, Prostate, Bladder

NuGenerex

NuGenerex Health

HEALTH

Ancillary health management services for chronic conditions

NuGenerex

Immuno Oncology

REGENERATIVE

Olaregen Therapeutix, Regentys

NuGenerex

Immuno Oncology

DIAGNOSTICS

NGDx Express II rapid diagnostic tests for infectious disease

NuGenerex

Immuno Oncology

THERAPEUTICS

Oral-lyn (Buccal Insulin) and RapidMist Buccal delivery technology

WELCOME TO GENEREX BIOTECHNOLOGY

Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians and ongoing relationships with patients to improve the patient experience and access to optimal care.

    In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital.

    End-to-End Solutions for patient centric care from rapid diagnosis through delivery of personalized therapies

    RECENT NEWS

    Generex Biotechnology Corporation Subsidiary, Olaregen Therapeutix Announces its Malaysian Distribution Partner, Nexgen Medical, has gained approval for the use of Excellagen® Wound Conforming Matrix from The Malaysian Ministry of Health, its country’s equivalent to the U.S. FDA

    MIRAMAR, Fla., July 26, 2021 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) subsidiary Olaregen Therapeutix announced in May that the company has executed a Distribution Agreement with Nexgen Medical Sdn Bhd, Inc. (“Nexgen”) to be...

    read more
    Generex Investor Call​​Click To Listen
    Generex Investor Call​​Click To Listen
    Generex Investor Call​​Click To Listen
    Generex Investor Call​​Click To Listen
    Generex Investor Call​​Click To Listen